Project: Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer

Acronym	PREVAlL (Reference Number: 11590)
Duration	01/03/2018 - 28/02/2021
Project Topic	The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). A range of preclinical safety and efficacy experiments will be performed to nominate a clinical candidate from a recently discovered and highly potent series of ERRa inhibitors. The new candidate drug will be supported by strong safety and efficacy data packages and be ready for clinical trials within 18 months after completion of the project.
Network	Eurostars 2
Call	Eurostars Cut-Off 7

Project partner

Number	Name	Role	Country
1	Lead Pharma Holding BV	Coordinator	Netherlands
2	3H Biomedical AB	Partner	Sweden
3	Axis Bioservices Ltd.	Partner	United Kingdom
4	Paraza Pharma Inc.	Partner	Canada